Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

Jon Thomas, CEO of CIRM, discusses the evolution of stem cell research and the future of regenerative medicine in this interview.

Unethical practices and forced labor exist in HPMC supply chains. Here’s what can be done about it.

Consider CIRM as a bank. We don’t conduct research ourselves: we fund it – and have become the largest dedicated funder of stem cell and gene therapy

Researchers demonstrate anticounterfeiting method that uses DNA oligos integrated into pharmaceutical products.

Controversial and divisive, but Kennedy’s expertise is intended for one thing: change.

From AI, to hot-melt extrusion, continuous processing, generics, and more – check out our free eBook.

Claus Zieler reflects on his time at Astellas and his role at EFPIA.